We read the paper by Levy et al 1 with interest, however, we believe that it contains several weaknesses which should be discussed.
As it is well known the diagnosis of GCA is based on the combination of clinical symptoms, laboratory test (CRP and ESR), and histopathology. 2 The treatment must be started immediately, thus the temporal artery biopsy result usually confirms presumed diagnosis made on the basis of clinical picture and laboratory tests.
It is well known that laboratory tests in GCA have some limited sensitivity: CRP 86.9% and ESR 84.1%. 2 Both combined gave specificity 97%, but it was shown and discussed in several studies that they might be normal in GCA: [2] [3] [4] [5] ESR was normal in 5-30% of patients with GCA. 3 The authors 1 inappropriately stated that 'including their case there are only three published cases of isolated CRP-negative GCA and only two cases of simultaneous ESR and CRP negativity' as they did not notice nor analyze many similar cases (Table 1) . Noteworthy, it was postulated that elevated ESR with normal CRP might occur even in 1.7% of GCA patients, 3 and that these markers can be normal at the early stage of the disease. 4 Having in mind problems with ESR and CRP in GCA, the role of clinical picture of the disease seems to be very important. They include usually headache, tenderness of the scalp, jaw claudication and some systemic symptoms, including malaise, fever, anorexia, and weight loss. 5 The symptoms are based on ischemia and/or inflammation. Thus, it is hard to understand why in the discussed case none of the clinicial symptomes was presented.
Concluding, we agree that diagnosis of GCA might be problematic, but it must be based on clinical picture and laboratory tests, including ESR and CRP, and confirmed by temporal artery biopsy. GCA with normal ESR and/or normal CRP level is rare, but many cases of this form of disease were already described. 12 We thank Dr Grzybowski and Justynska 1 for their interest in our article. In response to their comments on our report 2 we acknowledge the inadvertent omission of articles that emphasize the occurrence of inflammatory-marker-negative disease seen in giant cell arteritis (GCA). Unfortunately some papers referred to were not published at the time of writing. 3, 4 The table provided by Dr Grzybowski and Justynska highlights some important articles, some of which were referenced in our original report 5 and others which were summarized by key articles referenced. 6, 7, 8 Dr Grzybowski and Justynska remark that typical features commonly associated with GCA were not presented in our case. However, the patient we described was indeed unique in that the patient did not display symptoms usually found in GCA other than AIONinduced loss of vision and corresponding RAPD in a patient with known polymyalgia rheumatica. These features were described in our report. We fully agree that scrutinizing the clinical picture is critical in the diagnosis of GCA but would like to emphasize that this is exactly what we did. We specifically looked at the clinical presentation including increased pre-test probability due to ethnicity in order to come to the conclusion that the negative CRP needed to be ignored! We are very grateful for the additional case reports and have integrated them into our original table, thereby giving a more detailed understanding of inflammatorymarker-negative disease (Table 1) .
